«Physical activity
benefits lung cancer patients, survivors.»
Not exact matches
Merck's
cancer immunotherapy Keytruda is one of the pharma giant's rising stars, especially in the wake of evidence that the therapy had a survival
benefit over standard chemotherapy in advanced
lung cancer patients.
The biotech specialist said that its updated phase 2 data in a study of its poziotinib candidate treatment for non-small cell
lung cancer resulted in a preliminary confirmed objective response rate and potential progression - free survival
benefit in
patients with the EGFR Exon 20 Mutant form of the disease.
«Although some non-small cell
lung cancer patients have increased
benefit of targeted therapy or immunotherapy instead of chemotherapy, for some groups of
patients with NSNSCLC, chemotherapy has been the standard treatment for more than 30 years,» Gandhi notes.
Few existing treatments offer durable survival
benefits for
patients whose NSCLC has spread past the
lungs, due in part to the aggressive nature of
lung cancer and its propensity to progress, even following treatment.
Patients with epidermal growth factor receptor (EGFR) expressing advanced squamous non-small-cell
lung cancer benefit most from necitumumab added to gemcitabine and cisplatin chemotherapy, according to a subgroup analysis from the SQUIRE trial presented today at the European Lung Cancer Conference (ELCC) 2016 in Geneva, Switzerl
lung cancer benefit most from necitumumab added to gemcitabine and cisplatin chemotherapy, according to a subgroup analysis from the SQUIRE trial presented today at the European Lung Cancer Conference (ELCC) 2016 in Geneva, Switze
cancer benefit most from necitumumab added to gemcitabine and cisplatin chemotherapy, according to a subgroup analysis from the SQUIRE trial presented today at the European
Lung Cancer Conference (ELCC) 2016 in Geneva, Switzerl
Lung Cancer Conference (ELCC) 2016 in Geneva, Switze
Cancer Conference (ELCC) 2016 in Geneva, Switzerland.
This review shows uniform recognition that exercise and physical activity are safe for those with
lung cancer,
patients are requesting increased activity counseling, and multiple studies and reviews show potential clinical
benefit in quality of life, exercise tolerance, and post-operative complications.
The same
benefits of increased activity observed in
lung cancer patients, especially improved symptoms and quality of life, appear to apply to
lung cancer survivors as well.
However, «there are still large gaps in the published literature to be addressed and these could be filled with large definitive prospective trials that evaluate the
benefit of exercise in
lung cancer patients.»
Ongoing studies suggest it may
benefit patients with many different
cancers, including
lung, brain, head and neck, stomach, and kidney
cancers.
The work that garnered the honor, «An analysis of the risk and
benefit of neoadjuvant chemotherapy among
patients undergoing surgery for non-small cell
lung cancer,» examined data from more than 134,000 patients in the National Cancer Database to assess the impact of neoadjuvant therapy on perioperative outcomes, as well as long - term sur
cancer,» examined data from more than 134,000
patients in the National
Cancer Database to assess the impact of neoadjuvant therapy on perioperative outcomes, as well as long - term sur
Cancer Database to assess the impact of neoadjuvant therapy on perioperative outcomes, as well as long - term survival.
For
patients with non-small cell
lung cancer with brain metastases, treatment with whole brain radiotherapy may not offer much
benefit.
«Controversy unfortunately still exists among providers of the cost
benefit of screening,» he explained, «while
patients at risk of
lung cancer also lack adequate awareness of the
benefits of screening.»